Investors bought shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on weakness during trading on Thursday. $59.77 million flowed into the stock on the tick-up and $51.16 million flowed out of the stock on the tick-down, for a money net flow of $8.61 million into the stock. Of all companies tracked, Alexion Pharmaceuticals had the 29th highest net in-flow for the day. Alexion Pharmaceuticals traded down ($2.23) for the day and closed at $135.43

Several brokerages have commented on ALXN. Morgan Stanley reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Saturday, April 30th. BMO Capital Markets lowered Alexion Pharmaceuticals to a “buy” rating in a research report on Saturday, April 30th. Cowen and Company reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, April 17th. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Saturday, April 30th. Finally, Jefferies Group reissued a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, May 29th. Seven investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $184.27.

The stock’s 50 day moving average price is $124.82 and its 200-day moving average price is $139.35. The stock has a market capitalization of $30.75 billion and a price-to-earnings ratio of 344.50.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. The company earned $753 million during the quarter, compared to analysts’ expectations of $743.18 million. Alexion Pharmaceuticals’s revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.44 EPS. Analysts anticipate that Alexion Pharmaceuticals Inc. will post $4.65 earnings per share for the current year.

In related news, EVP Martin Mackay sold 4,097 shares of the company’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $139.20, for a total transaction of $570,302.40. Following the completion of the sale, the executive vice president now directly owns 42,706 shares in the company, valued at approximately $5,944,675.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John B. Moriarty sold 918 shares of the company’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $135.72, for a total value of $124,590.96. Following the sale, the executive vice president now owns 51,360 shares of the company’s stock, valued at $6,970,579.20. The disclosure for this sale can be found here.

Other large investors recently modified their holdings of the company. American International Group Inc. boosted its stake in shares of Alexion Pharmaceuticals by 1.2% in the fourth quarter. American International Group Inc. now owns 98,141 shares of the biopharmaceutical company’s stock worth $18,720,000 after buying an additional 1,203 shares during the period. I.G. Investment Management LTD. boosted its stake in shares of Alexion Pharmaceuticals by 4.6% in the fourth quarter. I.G. Investment Management LTD. now owns 31,750 shares of the biopharmaceutical company’s stock worth $6,056,000 after buying an additional 1,410 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Alexion Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 289,785 shares of the biopharmaceutical company’s stock worth $55,277,000 after buying an additional 6,189 shares during the period. KBC Group boosted its stake in shares of Alexion Pharmaceuticals by 46.7% in the third quarter. KBC Group now owns 22,138 shares of the biopharmaceutical company’s stock worth $3,462,000 after buying an additional 7,045 shares during the period. Finally, Aberdeen Asset Management PLC UK boosted its stake in shares of Alexion Pharmaceuticals by 17.8% in the fourth quarter. Aberdeen Asset Management PLC UK now owns 61,840 shares of the biopharmaceutical company’s stock worth $10,313,000 after buying an additional 9,357 shares during the period.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.